Ivana Cengic1, Inés C Cañadas2, Nigel P Minton2, Elton P Hudson1. 1. School of Engineering Sciences in Chemistry, Biotechnology and Health, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm 17121, Sweden. 2. BBSRC/EPSRC Synthetic Biology Research Centre (SBRC), School of Life Sciences, The University of Nottingham, Nottingham NG7 2RD, U.K.
Abstract
Establishing various synthetic biology tools is crucial for the development of cyanobacteria for biotechnology use, especially tools that allow for precise and markerless genome editing in a time-efficient manner. Here, we describe a riboswitch-inducible CRISPR/Cas9 system, contained on a single replicative vector, for the model cyanobacterium Synechocystis sp. PCC 6803. A theophylline-responsive riboswitch allowed tight control of Cas9 expression, which enabled reliable transformation of the CRISPR/Cas9 vector intoSynechocystis. Induction of the CRISPR/Cas9 mediated various types of genomic edits, specifically deletions and insertions of varying size. The editing efficiency varied depending on the target and intended edit; smaller edits performed better, reaching, e.g., 100% for insertion of a FLAG-tag onto rbcL. Importantly, the single-vector CRISPR/Cas9 system mediated multiplexed editing of up to three targets in parallel inSynechocystis. All single-target and several double-target mutants were also fully segregated after the first round of induction. Lastly, a vector curing system based on the nickel-inducible expression of the toxic mazF (from Escherichia coli) was added to the CRISPR/Cas9 vector. This inducible system allowed for curing of the vector in 25-75% of screened colonies, enabling edited mutants to become markerless.
Establishing various synthetic biology tools is crucial for the development of cyanobacteria for biotechnology use, especially tools that allow for precise and markerless genome editing in a time-efficient manner. Here, we describe a riboswitch-inducible CRISPR/Cas9 system, contained on a single replicative vector, for the model cyanobacterium Synechocystis sp. PCC 6803. A theophylline-responsive riboswitch allowed tight control of Cas9 expression, which enabled reliable transformation of the CRISPR/Cas9 vector intoSynechocystis. Induction of the CRISPR/Cas9 mediated various types of genomic edits, specifically deletions and insertions of varying size. The editing efficiency varied depending on the target and intended edit; smaller edits performed better, reaching, e.g., 100% for insertion of a FLAG-tag onto rbcL. Importantly, the single-vector CRISPR/Cas9 system mediated multiplexed editing of up to three targets in parallel inSynechocystis. All single-target and several double-target mutants were also fully segregated after the first round of induction. Lastly, a vector curing system based on the nickel-inducible expression of the toxic mazF (from Escherichia coli) was added to the CRISPR/Cas9 vector. This inducible system allowed for curing of the vector in 25-75% of screened colonies, enabling edited mutants to become markerless.
Cyanobacteria are photosynthetic prokaryotes
that have gained interest
as cell factories for sustainable production of various compounds.[1−3] However, in order for large-scale processes to become economically
feasible, further study and significant engineering of these cyanobacterial
hosts is required. While the toolset to engineer cyanobacteria is
steadily growing,[4−6] there is still need for reliable tools that allow
for precise, markerless, rapid, and multiplexed editing in these polyploid
organisms[7] that are commonly time-consuming
to engineer.The CRISPR/Cas genome editing system is one such
promising tool.[8−12] A guide RNA (gRNA) is provided to guide the Cas endonuclease to
a specific complementary target DNA site (the protospacer). This protospacer
target must be next to a protospacer adjacent motif (PAM). Binding
of the Cas-gRNA effector complex to the target DNA results in a double-stranded
break (DSB) that is lethal for the cell unless mended. The most common
method to mend DSBs in prokaryotes is by homology-directed repair
(HDR), whereby a donor DNA is provided as a repair template. The Cas
protein first popularized for widespread use was the class 2, type
II Cas9 protein from Streptococcus pyogenes.[9,13] However, besides being an efficient endonuclease
it can also be cytotoxic when overexpressed, both alone and particularly
when coexpressed with a single guide RNA (sgRNA), resulting in low
transformation efficiencies and few edited transformants.[14] Some strategies to circumvent Cas9 toxicity
are to identify and use alternative endonucleases, to engineer endogenous
bacterial CRISPR systems, or to decouple the transformation and editing
steps by having inducible expression of Cas9.[14]Several CRISPR/Cas systems have been described for cyanobacteria.
In the two first studies, performed in Synechococcus UTEX 2973 and Synechococcus elongatus PCC 7942, transient expression of Cas9 supported editing, although
cytotoxicity was a noted issue.[15,16] In a later study, constitutive
expression of the less toxic Cpf1 (also named Cas12a) endonuclease
proved useful to mediate various types of edits (point mutation, knock-out,
and knock-in) in UTEX 2973, Synechocystis sp. PCC 6803 (hereafter S6803), and Anabaena sp. PCC 7120.[17] However, several passages
on selective media were required to increase the percentage of edited
and fully segregated colonies, especially in the highly polyploid
S6803. This Cpf1-system was further evaluated in Anabaena, where it facilitated sequential and simultaneous deletion of two
genes, and was supplemented with a counter-selection tool to cure
edited cells of the Cpf1-plasmid.[18] Only
one example of an inducible CRISPR/Cas9 system has, to our knowledge,
been described for cyanobacteria. There, cas9 was
integrated into the genome of the S6803 host and its expression was
controlled by an aTc-inducible promoter.[19] However, leaky Cas9 expression in uninduced cells caused low transformation
efficiencies (∼10 CFU/μg DNA) for sgRNA-expressing plasmids.
An alternative method using site-specific recombinases has also been
used to make markerless genome edits in Synechococcus sp. PCC 7002 and S6803;[20] however, this
method still leaves short recombination scars at the edit sites unlike
CRISPR/Cas9 which supports scarless edits.Development of tightly
controlled CRISPR/Cas9 systems has until
now been more successful in other types of bacteria.[14,21−23] While many studies have used the traditional pairing
of inducible promoter and transcriptional regulator, several recent
studies have successfully employed riboswitches as regulatory elements
for Cas9 expression.[24−26] Riboswitches are small structured RNA elements commonly
found in the 5’-UTR of mRNAs.[27,28] Their small
size is especially useful when building CRISPR/Cas systems contained
on single plasmids. The aptamer domain of a riboswitch is able to
selectively bind to a specific ligand, triggering a conformational
change that affects the expression platform domain and thus regulates
the expression of the downstream gene.[27] Often this regulation occurs at the transcriptional or translational
level.The riboswitches used to control CRISPR/Cas9 systems
in bacteria
have been based mainly on the synthetic theophylline-specific aptamer.[29] This aptamer was used by Topp et al. to develop
a set of six theophylline-inducible riboswitches (A – E + E*),
widely applicable in different bacteria.[30] These riboswitches regulate the expression of a downstream gene
at the translational level by blocking access to the mRNA’s
ribosome binding site (RBS) when no theophylline ligand is bound.
When theophylline binds, the RBS is made available and translation
can proceed. These theophylline riboswitches have already been evaluated
in various cyanobacteria,[31−34] and used in developing tools such as NOT gates in,
e.g., S6803,[33] inducible protein degradation
systems in S. elongatus PCC 7942,[35,36] and inducible CRISPR-interference systems in S6803 and Anabaena.[37,38] In this study, they
were further used to design a tightly controlled CRISPR/Cas9 system
for inducible genome editing in S6803.
Results and Discussion
Designing the Riboswitch-Based Inducible CRISPR/Cas9 System
for S6803
The goal of this study was to build a tightly controlled
CRISPR/Cas9 system for S6803, where the expression of Cas9, and therefore
genome editing, is controlled by a theophylline-inducible riboswitch.
This system was built to be self-contained on a single plasmid based
on the replicative pPMQAK1-T vector with an RSF1010-replicon.[39,40]Of note is that the S6803 host used in this study is highly
polyploid, with, on average, 20 genome copies observed during exponential
growth.[7] Any promising CRISPR/Cas9 system
must therefore be able to edit all genomic copies of the intended
target DNA to produce a fully segregated mutant. As the level of Cas9
required to achieve such editing in S6803 is unknown, three different
riboswitches from the set developed by Topp et al.[30] were tested to control its expression. The aim was to identify
which one would provide the correct balance of nonleaky Cas9 expression
when un-induced, allowing high transformation efficiency of the CRISPR/Cas9
vector, and high enough expression when induced to allow for successful
genome editing. The two riboswitches shown to have the least leaky
expression in S6803, B and C,[33] were selected.
The more leaky variant E* was also selected,[33] to include a riboswitch that supports a higher induced expression
level if needed.In a preliminary part of this study, these
riboswitches were combined
with the conII promoter (P) as has been done in several cyanobacteria studies.[32,33] However, no useful system resulted from these efforts, which is
mainly due to inefficiently induced CRISPR/Cas9 genome editing (data
not shown). In a new attempt, the same riboswitches were instead combined
with the trc promoter (P) as described by Nakahira et al.;[31] this also meant adding the P 5′-UTR
and a constant region upstream of the riboswitches. Note that the
LacI repressor was not expressed in any of the strains in this study,
so the inducibility of P was only due
to its combination with the riboswitches. To ensure that the theophylline
concentrations used to induce the riboswitches would not be toxic,
its toxicity toward S6803 was evaluated (Figure S1). At 0.5 mM theophylline, there was no apparent growth defect,
either in culture or on plates.The effect of changing the promoter
and 5’-UTR region upstream
of the riboswitches was studied with a Gfp reporter (Figure S2). The P variants
supported higher expression levels and induction ratios than the P ones. P-[B] and P[E*] showed maximum induction
ratios of 68- and 30-fold at 0.5 mM theophylline, respectively. The
higher induction ratio for P-[B] compared
to P-[E*] was due to less leaky expression,
as P-[E*] allowed a 7-fold higher absolute
expression level. In comparison, P-[C]
underperformed due to leaky and weak expression and only reached a
maximum 14-fold induction at 0.5 mM.Two strategies to additionally
lower the Cas9-levels in uninduced
cells were explored. One was to add an ssrA protease
degradation tag to the C-terminus of Cas9.[21] The selected tag (LVA) has been estimated to reduce the steady-state
level of a tagged protein by 95% in S6803.[39,41] The other strategy was to mutate the −10-box in P to emulate −10 boxes found in weaker promoters.[42] The P shares
the same −10-box (TATAAT) as the strong BioBrick BBa_J23119
promoter, which belongs to a promoter library that has been evaluated
in S6803.[40] Promoters from this library
that drive weaker expression and that only differ in their −10-box
sequence were used to select the alternative −10-boxes. These
selected ones came from promoters BBa_J23104 (TATTGT), BBa_J23116
(GACTAT), and BBa_J23117 (GATTGT). These were hereafter identified
by their last three digits (104, 116, 117) and were estimated to weaken
P by roughly 65%, 90%, and 99%, respectively.
These two weakening strategies were applied separately from each other
to all P riboswitch (B, C, or E*) pairs.In total, this created 15 different pPMQAK1-CRISPR/Cas9 base vectors
to evaluate. All vectors were constructed in the same way for ease
of use; the cas9 expression cassette was followed
by a lacZ sandwiched between two Golden Gate cloning
BsaI sites (Figures a and S3a for a more detailed vector map).
The pieces specific to the target DNA, the sgRNA and donor DNA, were
constructed with compatible BsaI sites (Figure a), enabling simultaneous ligation of both
into the base vector to create the final target vector (Figure b).
Figure 1
Overview of the pPMQAK1-CRISPR/Cas9
vector build and general workflow.
(A) Schematic showing the pPMQAK1-CRISPR/Cas9 base vector and target
DNA-specific pieces, i.e., sgRNA and donor DNA, with the BsaI overhangs
required for one-step Golden Gate assembly. The vector variants differ
in their expression of cas9: one of three riboswitches
(“ribosw.”) mediate induction with theophylline, P has −10-boxes with differing strengths
(−10*), and some variants include an LVA-tagged Cas9 (±LVA).
(B) Map of the final pPMQAK1-CRISPR/Cas9 target vector.(C) Workflow
to transform (by electroporation) a constructed pPMQAK1-CRISPR/Cas9
target vector into S6803 and induce CRISPR/Cas9-mediated editing.
Approximate time for each step is indicated.
Overview of the pPMQAK1-CRISPR/Cas9
vector build and general workflow.
(A) Schematic showing the pPMQAK1-CRISPR/Cas9 base vector and target
DNA-specific pieces, i.e., sgRNA and donor DNA, with the BsaI overhangs
required for one-step Golden Gate assembly. The vector variants differ
in their expression of cas9: one of three riboswitches
(“ribosw.”) mediate induction with theophylline, P has −10-boxes with differing strengths
(−10*), and some variants include an LVA-tagged Cas9 (±LVA).
(B) Map of the final pPMQAK1-CRISPR/Cas9 target vector.(C) Workflow
to transform (by electroporation) a constructed pPMQAK1-CRISPR/Cas9
target vector into S6803 and induce CRISPR/Cas9-mediated editing.
Approximate time for each step is indicated.The promoter selected for sgRNA expression was
the constitutive
but weak BioBrick BBa_J23117.[40] Weak sgRNA
expression was deemed to complement the inducible CRISPR/Cas9 system
better, since unnecessary overexpression could exacerbate the action
of any leaky Cas9. To select the spacers used in the sgRNAs, the Cas9-specific
NGG-PAM was used to search the target DNA area for suitable protospacers.
The sgRNAs were designed to target as close to the desired edit site
as possible, considering that Cas9 cuts 3–4 nucleotides upstream
of the PAM.[12] A short distance between
the DSB and edit site is correlated with better editing efficiency.[43] The sgRNAs were also constructed to target the
template strand (unless noted otherwise); this allows for faster dislodging
of the Cas9-sgRNA complex from the cut site, enabling improved access
for the HDR machinery.[44]Depending
on the desired genome edit, the donor DNA was altered
accordingly. Generally, the donor DNA included 350 bp homology arms
on either side of the edit site, and was designed to remove or silently
mutate the PAM and proximal protospacer sequence to avoid recognition
and continued cutting of the target site after editing.The
workflow (Figure c)
used in this study took advantage of the decoupling of transformation
and genome editing made possible by having inducible Cas9 expression.
Plating of transformed, by electroporation, and recovered S6803 on
noninducer plates resulted in many transformants for the pPMQAK1-CRISPR/Cas9
target vector. These transformants were subsequently plated on inducer
plates to undergo CRISPR/Cas9-mediated genome editing. Surviving colonies
were screened for the desired edit. To control that the constructed
pPMQAK1-CRISPR/Cas9 target vector was functional in mediating DSBs,
i.e., had an efficient sgRNA, half of the transformed and recovered
S6803 were plated directly on inducer plates. If the DNA targeting
was functional, these yielded no or very few surviving transformants
due to the lethality of DSBs and low efficiency of HDR. If any transformants
survived, they were screened for the desired edit.
Proof-of-Principle Test To Identify Promising CRISPR/Cas9 Base
Vectors
To narrow down the set of the 15 designed pPMQAK1-CRISPR/Cas9
base vectors, a proof-of-principle test was done. The goal was to
introduce a small 20 bp deletion into the yfp gene
of a S6803 Δslr1181::P-Yfp-B0015-Spr strain (Figure a). An sgRNA targeting close to the middle
of yfp was selected, while the desired 20 bp deletion
included removal of the GGG-PAM and preceding three bases of the protospacer.
The donor DNA contained homology arms surrounding the deletion site.
All 15 resulting CRISPR/Cas9 yfp target vectors were
transformed into strain Δslr1181::P-Yfp-B0015-Spr and treated according
to the workflow in Figure c. A control vector where cas9 lacked a promoter
and start codon, i.e., resulting in no expression, was also included.
This vector served as a control for the toxicity exhibited by any
potentially leaky Cas9 expression in the tested vector variants. Its
similarly large size (only 160 bp smaller) also worked as a control
for the transformation efficiency for such large vectors (∼13
kbp) into S6803.
Figure 2
Evaluating the built pPMQAK1-CRISPR/Cas9 vectors in S6803
by performing
a small deletion. (A) Schematic of the genomic yfp target in S6803 Δslr1181::P-Yfp-B0015-Spr, showing approximate placement of
the sgRNA target region (black box) and desired 20 bp deletion. (B)
Transformation results after plating on selective plates without or
with 0.25 mM theophylline inducer. The 15 yfp-targeting
pPMQAK1-CRISPR/Cas9 vector variants differ in their cas9-expression strength, and the P is
fused to riboswitch B, C, or E* and evaluated as is, in combination
with a degradation tag (+LVA) on Cas9, or with a weakened P by changing its original −10-box (strength:
original > 104 > 116 > 117). The control lacks cas9 expression. (C) Induction spot assay results for [B], [B] + LVA,
and [E*](104), and the control. 5× dilution series were plated
on regular BG11-plates or plates supplemented with 0.25 or 0.5 mM
theophylline inducer. Done for biological triplicates in technical
duplicates, representative data is shown. (D) Editing results for
[B], [B] + LVA, and [E*](104). A green line below a lane signals a
fully edited (Δ20 bp) mutant. A control (“C”)
shows how an unedited colony will appear. Fractions indicate the number
of fully edited colonies out of the total number screened. Two representative
colony phenotypes were screened for [B] + LVA induced on 0.5 mM theophylline.
(E) Percentage of CFUs that retained a healthy phenotype (i.e., survived)
and became edited, after being induced on 0.25 or 0.5 mM theophylline.
Bars show the averages ± SD for induced biological triplicates
(different symbols, i.e., a circle, triangle, or square, distinguishes
the data for each triplicate) done in technical duplicates. (F) Example
of the two representative phenotypes found on inducer plates, i.e.,
healthier, greener colonies (indicated by arrows and marked “G”),
and bleaching colonies (circled and marked “B”).
Evaluating the built pPMQAK1-CRISPR/Cas9 vectors in S6803
by performing
a small deletion. (A) Schematic of the genomic yfp target in S6803 Δslr1181::P-Yfp-B0015-Spr, showing approximate placement of
the sgRNA target region (black box) and desired 20 bp deletion. (B)
Transformation results after plating on selective plates without or
with 0.25 mM theophylline inducer. The 15 yfp-targeting
pPMQAK1-CRISPR/Cas9 vector variants differ in their cas9-expression strength, and the P is
fused to riboswitch B, C, or E* and evaluated as is, in combination
with a degradation tag (+LVA) on Cas9, or with a weakened P by changing its original −10-box (strength:
original > 104 > 116 > 117). The control lacks cas9 expression. (C) Induction spot assay results for [B], [B] + LVA,
and [E*](104), and the control. 5× dilution series were plated
on regular BG11-plates or plates supplemented with 0.25 or 0.5 mM
theophylline inducer. Done for biological triplicates in technical
duplicates, representative data is shown. (D) Editing results for
[B], [B] + LVA, and [E*](104). A green line below a lane signals a
fully edited (Δ20 bp) mutant. A control (“C”)
shows how an unedited colony will appear. Fractions indicate the number
of fully edited colonies out of the total number screened. Two representative
colony phenotypes were screened for [B] + LVA induced on 0.5 mM theophylline.
(E) Percentage of CFUs that retained a healthy phenotype (i.e., survived)
and became edited, after being induced on 0.25 or 0.5 mM theophylline.
Bars show the averages ± SD for induced biological triplicates
(different symbols, i.e., a circle, triangle, or square, distinguishes
the data for each triplicate) done in technical duplicates. (F) Example
of the two representative phenotypes found on inducer plates, i.e.,
healthier, greener colonies (indicated by arrows and marked “G”),
and bleaching colonies (circled and marked “B”).The desired result was a CRISPR/Cas9 target vector
that resulted
in many transformants under noninduced conditions but was proven effective
in inducing lethal DSBs when induced with theophylline. The transformation
results (Figure b)
clearly singled out constructs P-[B]-Cas9
(hereafter named [B]), P-[B]-Cas9 +
LVA (hereafter named [B] + LVA), and P(−10-box:104)-[E*]-Cas9 (hereafter named [E*](104)) as having
these desirable traits. Based on the previous Gfp reporter results
(Figure S2), and what is known about the
modifications introduced to weaken the expression or stability of
Cas9 in these constructs, these systems were estimated to rank as
follows in terms of resulting Cas9 amounts: [E*](104) > [B] >
[B]
+ LVA. The control showed that 0.25 mM theophylline alone did not
affect the transformation efficiency.Colonies from the transformation
plates (Figure S4a) were screened to check for leaky editing in the absence
of any inducer, and if the few surviving transformants on the theophylline
plates (Figure S4a,b) were indeed edited
or had remained unedited by somehow “escaping” the CRISPR/Cas9.
While no leaky editing was observed for the uninduced transformants,
a fraction of the surviving induced transformants were fully edited,
with editing efficiencies of 25–87.5% depending on the construct
(Figure S4c). This showcases the tight
control of these CRISPR/Cas9 systems and also the possibility of obtaining
fully edited transformants directly after electroporation.To
further evaluate the CRISPR/Cas9-induction and yfp (Δ20 bp) editing efficiency of the promising [B], [B] + LVA,
and [E*](104) constructs, triplicate transformants were induced on
plates with theophylline. The promoterless-cas9 vector
was included as a control. In an attempt to titrate the Cas9 expression,
induction on 0.25 and 0.5 mM theophylline was compared. The resulting
representative spot assays (Figure c) expectedly showed widespread cell death due to induction
of the CRISPR/Cas9 system. To determine the yfp (Δ20
bp) editing efficiency, surviving colonies that appeared healthy on
the inducer plates were picked and screened by colony-PCR (Figure d). While no construct
reached 100% editing efficiency, all edited colonies were fully segregated
after just one round of induction. In addition, the editing efficiencies
for the two tested theophylline concentrations were comparable, showing
that higher induction was not necessary. Overall, the stronger Cas9
expressing construct [E*](104) supported the best yfp (Δ20 bp) editing efficiency, reaching 54% for both tested
inducer concentrations. To better judge the difference between the
two tested theophylline concentrations and CRISPR/Cas9 constructs,
the respective editing efficiency for the screened colonies was related
to the percentage of CFUs that retained a healthy and green phenotype
(i.e., “survived”) after induction (see the Methods section for details). This quantified the
total percentage of induced CFUs that survived induction and became
edited. The weakest [B] + LVA construct was found to benefit from
increased Cas9 expression at 0.5 mM theophylline (Figure e). Meanwhile, induction with
0.25 mM outperformed 0.5 mM for constructs [B] and [E*](104) (Figure e), due to fewer
cells surviving on the higher concentration (Figure c). Taken together, the decision was made
to use the lower 0.25 mM theophylline concentration for the rest of
this study.Among the colonies that appeared on plates after
CRISPR/Cas9-induction,
two different phenotypes were observed. One type was greener and larger,
while the second was smaller and slightly bleached (Figure f). This second phenotype was
more prevalent for the weakest [B] + LVA construct and was responsible
for the apparent higher survival of these cells on theophylline (Figure c). When these two
colony types were compared in terms of yfp (Δ20
bp) editing for construct [B] + LVA, only the larger, greener ones
exhibited any fully segregated edits (Figure d). Also, after prolonged induction on theophylline
the smaller colonies were found to bleach entirely and die (Figure S4d), likely due to incomplete or absent
editing and continued exposure to lethal Cas9-catalyzed DSBs. This
phenotypic difference, if prevalent after induction, can therefore
be useful when choosing which obtained colonies are to be screened.
This strategy was applied throughout this continued study; only the
greener and therefore healthier-looking colonies were assessed for
genome editing.
Exploring the Edit Types Possible with This Inducible CRISPR/Cas9
Tool
The promising [B], [B] + LVA, and [E*](104) CRISPR/Cas9
vectors were further evaluated for their ability to perform other
types of genomic edits in S6803.To perform a large deletion,
the entire P-Yfp-B0015-Spr cassette (Δ2240 bp) in the Δslr1181::P-Yfp-B0015-Spr strain
was targeted (Figure a). The same yfp-targeting sgRNA as used previously
for the small 20 bp deletion was reused here. Although this sgRNA
binds in the middle of yfp (Figure a), far from the edit site, such targeting
has been shown to work for CRISPR/Cpf1 deletions in Anabaena.[18] The donor
DNA was changed to feature 350 bp homology arms on either side of
the slr1181 integration site. Transformation of the
[B], [B] + LVA, and [E*](104) yfp-targeting vectors
into S6803 resulted in many transformants (Figure S5). Induction of the CRISPR/Cas9 gave few surviving colonies
(Figure b), the weakest
[B] + LVA construct yielded only bleaching colonies (data not shown)
and was not considered further for this target. For induced [B] and
[E*](104) transformants, the editing efficiencies were 67 and 33%,
respectively (Figure c). Despite the higher editing efficiency for construct [B], the
total percentage of induced CFUs that survived and became edited was
higher for the stronger construct [E*](104) (Figure d). One outlier for [E*](104) was especially
successful.
Figure 3
Testing various CRISPR/Cas9-edit types in S6803: (A–D) large
deletion of a P-Yfp-B0015-Spr cassette, (E–I) small insertion of a FLAG-tag onto rbcL, and (J–L) large insertion of a P-Yfp-B0015 cassette. (A, E, J) Schematics of
the different targets in S6803, showing approximate placement of the
sgRNA target region (black box) and intended edits. For (E), the TAA
stop codon is underlined, the CGG-PAM shown in bold. Mutations introduced
in the edit are shown in red. (B, F, K) Induction spot assay results
for specified CRISPR/Cas9 constructs. 5× dilution series were
plated on plates without or with 0.25 mM theophylline. Done for biological
triplicates, representative data is shown. (C, G, L) Editing results
for specified CRISPR/Cas9 constructs. A green line below a lane signals
a fully edited mutant. Fractions indicated the number of fully edited
colonies out of the total number screened. For (C) “C”
and “KO” indicate the band size for an unedited and
edited colony, respectively. For (L), “wt” and “KI”
indicate the band size for an unedited and edited colony, respectively.
(D, H) Percentage of induced CFUs that survived (i.e., retained a
healthy phenotype) and became edited. Bars show the averages ±
SD from biological triplicates, individual values are also shown.
(I) Western blot of a fully edited mutant expressing RbcL-FLAG, compared
to a wt control; 15 μg protein from the soluble fraction was
loaded and probed using an anti-FLAG IgG.
Testing various CRISPR/Cas9-edit types in S6803: (A–D) large
deletion of a P-Yfp-B0015-Spr cassette, (E–I) small insertion of a FLAG-tag onto rbcL, and (J–L) large insertion of a P-Yfp-B0015 cassette. (A, E, J) Schematics of
the different targets in S6803, showing approximate placement of the
sgRNA target region (black box) and intended edits. For (E), the TAA
stop codon is underlined, the CGG-PAM shown in bold. Mutations introduced
in the edit are shown in red. (B, F, K) Induction spot assay results
for specified CRISPR/Cas9 constructs. 5× dilution series were
plated on plates without or with 0.25 mM theophylline. Done for biological
triplicates, representative data is shown. (C, G, L) Editing results
for specified CRISPR/Cas9 constructs. A green line below a lane signals
a fully edited mutant. Fractions indicated the number of fully edited
colonies out of the total number screened. For (C) “C”
and “KO” indicate the band size for an unedited and
edited colony, respectively. For (L), “wt” and “KI”
indicate the band size for an unedited and edited colony, respectively.
(D, H) Percentage of induced CFUs that survived (i.e., retained a
healthy phenotype) and became edited. Bars show the averages ±
SD from biological triplicates, individual values are also shown.
(I) Western blot of a fully edited mutant expressing RbcL-FLAG, compared
to a wt control; 15 μg protein from the soluble fraction was
loaded and probed using an anti-FLAG IgG.Next, a small genomic insertion was tested. The
aim was to add
a C-terminal FLAG-tag (24 bp) to the large subunit of Rubisco (rbcL) (Figure e). Many proteins of interest lack available antibodies, so the ability
to introduce a markerless tag that does not disrupt the region surrounding
the gene is a valuable tool. The position of this edit needed to be
more specific than the previous deletions, as the FLAG-tag must be
added in-frame in front of the rbcL stop codon (TAA).
The protospacer options in this region were evaluated, and an sgRNA
was designed to introduce the DSB two nucleotides from the desired
edit site. As the CGG-PAM and parts of the proximal protospacer could
not be deleted in this instance, they were instead mutated to stop
the edited target from being recognized by the Cas9-sgRNA complex
(Figure e). Transformation
of the [B], [B] + LVA, and [E*](104) rbcL-target
vectors into S6803 resulted in many transformants (Figure S6a). For constructs [B] + LVA and [E*](104), colonies
that survived on the inducer plates directly after transformation
were already fully edited (Figure S6b).
Inducing CRISPR/Cas9 in the transformants gave few surviving colonies
(Figure f) but enough
so the healthy colony phenotype could be found for all three tested
vectors (Figure S6c). The editing efficiency
was found to be 100% for all three rbcL-targeting
constructs (Figure g). The higher editing efficiency supported for this edit, compared
to the yfp one mentioned previously, is likely due
to a higher on-target efficiency of the rbcL-targeting
sgRNA. Despite this, the total percentage of induced CFUs that survived
and became edited was not much higher (Figure h). The soluble protein fraction from one
of the edited colonies was subjected to immunoblotting using an anti-FLAG
IgG. Here, the product of the edited rbcL, i.e.,
the RbcL-FLAG, could be clearly detected (Figure i).As a final test, an attempt was
made to insert the whole P-Yfp-B0015
cassette into neutral site slr0168 (Figure j). This cassette lacked an
antibiotic resistance marker,
meaning that selection was done only by colonies surviving the Cas9-induced
DSBs. The sgRNA was designed to target slr0168, and
the donor DNA was supplied as three separate pieces when assembling
the target vector: one piece for the whole P-Yfp-B0015-cassette and one piece each for the upstream and
downstream homologous regions (350 bp each). The donor DNA was also
designed to remove the TGG-PAM and preceding three bases of the protospacer.
Transformation of the [B], [B] + LVA, and [E*](104) target vectors
into S6803 resulted in transformants (Figure S7) but fewer than those seen for other target vectors previously.
Induction of CRISPR/Cas9 gave many surviving colonies that exhibited
the healthier phenotype (Figure k). However, editing efficiencies among the screened
colonies was low (Figure l), as only a single fully edited colony (+1222 bp) was found
per construct. It has been shown in E. coli that CRISPR/Cas9 editing efficiency is negatively correlated with
an increase in insertion length,[45] likely
explaining the lower efficiency seen for this Yfp cassette insertion.
This efficiency could possibly be improved by extending the length
of the homology arms in the donor DNA;[45] however, this was not explored here.
Inducible Multiplexed CRISPR/Cas9 Editing in S6803
Multiplexed, simultaneous editing capabilities could greatly accelerate
strain engineering in S6803. Considering the higher editing efficiencies
of the smaller edits described above, these were selected for multiplexing
tests. Such small edits can be used to modify promoter regions to
alter gene expressions or to introduce premature stop codons to knock-out
genes.As a proof-of-principle study, the preliminary goal was
to target four neutral sites (NSs) in the S6803 genome and introduce
small deletions (Δ30 bp) into all of them with a single pPMQAK1-CRISPR/Cas9
target vector. The NSs were NS1 (slr0168), NS2 (slr1181), NS3 (slr2030–2031), and NS4 (slr0397); see Figure a for the respective sgRNA target regions.
The donor DNAs had 350 bp homology arms; the 30 bp deletions included
removal of the PAM sites and preceding three bases of the protospacers.
Figure 4
(A) Schematics
of the S6803 neutral site (1–4) targets,
showing approximate placement of the sgRNA target region (black box)
and intended edit (Δ30 bp). (B) Percentage of induced CFUs that
survived (retained a healthy phenotype) and became edited, for the
individual editing of the NS1, NS3, and NS4 targets. Bars show the
averages ± SD from biological duplicates, individual values are
also shown. An outlier for [E*](104), target NS1, is not included
in the graph but indicated by an arrow.
(A) Schematics
of the S6803 neutral site (1–4) targets,
showing approximate placement of the sgRNA target region (black box)
and intended edit (Δ30 bp). (B) Percentage of induced CFUs that
survived (retained a healthy phenotype) and became edited, for the
individual editing of the NS1, NS3, and NS4 targets. Bars show the
averages ± SD from biological duplicates, individual values are
also shown. An outlier for [E*](104), target NS1, is not included
in the graph but indicated by an arrow.The sgRNA and donor DNA for each of the four targets
was first
tested individually with the [B], [B] + LVA, and [E*](104) base vectors.
Many transformants were obtained for most constructs, with the exception
of the NS1- or NS4-targeting [E*](104) constructs (Figure S8). Likely the sgRNAs designed for these two targets
are highly efficient, exacerbating the effect of any leaky Cas9 expression
from the stronger [E*](104) construct. Induction of CRISPR/Cas9 in
these single-target transformants gave varying results depending on
the target (Figure S9). When calculating
the percentage of induced CFUs that survived and became edited, the
best results were seen for targets NS1 and NS4, followed by NS3 (Figure b). For NS2, no edited
colonies were found (Figure S9d), removing
this target from further consideration.Based on these results,
it was decided to combine targets NS1 and
NS4 in a double-edit target vector, and add the less efficient, but
still functional NS3 for a triple-edit target vector. To construct
the multiplex target vectors, first the individual sgRNAs were combined
by Golden Gate assembly to form a single sgRNA array, which was then
combined with the separate donor DNA pieces for simultaneous ligation
into the pPMQAK1-CRISPR/Cas9 base vector (Figure a). Again, the [B], [B] + LVA, and [E*](104)
base vectors were all tested.
Figure 5
Inducible multiplexed CRISPR/Cas9 editing in
S6803. (A) Schematic
of the sgRNA and donor DNA pieces built for constructing a multitarget
pPMQAK1-CRISPR/Cas9 target vector. The sgRNAs are supplied as a one-piece
array, with the same overhangs as a single sgRNA. The donor DNA pieces
are supplied as separate parts, with unique overhangs between the
donors (NNNN), and the standard overhangs on the
outermost ends. (B) Induction spot assay results for triplicate transformants
of the [B] double- and triple-target constructs. 5× dilution
series were plated on plates with or without 0.25 mM theophylline.
(C) Editing results for the induced [B] double-target (NS1 + NS4)
construct. (D) Editing results for the induced [B] triple-target (NS1
+ NS3 + NS4) construct. (C, D) A green line below a lane signals a
fully segregated multiedit in that screened colony. Colonies that
appear segregated but have not been marked as such are due to them
having detectable wt bands when the gels are more closely inspected.
Fractions indicated the number of fully edited colonies out of the
total number screened. A wt control shows how an unedited colony will
appear. An “R” below a lane indicates a not fully segregated
mutant that was restreaked for a second round of induction.
Inducible multiplexed CRISPR/Cas9 editing in
S6803. (A) Schematic
of the sgRNA and donor DNA pieces built for constructing a multitarget
pPMQAK1-CRISPR/Cas9 target vector. The sgRNAs are supplied as a one-piece
array, with the same overhangs as a single sgRNA. The donor DNA pieces
are supplied as separate parts, with unique overhangs between the
donors (NNNN), and the standard overhangs on the
outermost ends. (B) Induction spot assay results for triplicate transformants
of the [B] double- and triple-target constructs. 5× dilution
series were plated on plates with or without 0.25 mM theophylline.
(C) Editing results for the induced [B] double-target (NS1 + NS4)
construct. (D) Editing results for the induced [B] triple-target (NS1
+ NS3 + NS4) construct. (C, D) A green line below a lane signals a
fully segregated multiedit in that screened colony. Colonies that
appear segregated but have not been marked as such are due to them
having detectable wt bands when the gels are more closely inspected.
Fractions indicated the number of fully edited colonies out of the
total number screened. A wt control shows how an unedited colony will
appear. An “R” below a lane indicates a not fully segregated
mutant that was restreaked for a second round of induction.Transformation of the multiplex target vectors
into S6803 generally
resulted in fewer transformants than that seen previously for the
single-target vectors (Figure S10). The
number of colonies was negatively correlated with the number of targets
and expression strength of the CRISPR/Cas9 construct. Still, enough
transformants were available that all constructs could be tested.In a first test, precultures of the transformants were prepared
prior to induction. However, this precultivation step appeared to
select for cells that had mutated the CRISPR/Cas9 machinery, as most
induced cells grew normally on theophylline and very few edits were
found in the screened colonies (data not shown). A second attempt
was done where the transformants were picked and plated directly on
inducer plates (see the Methods section).
The representative spot assays now showed more promising results,
with fewer cells surviving on the theophylline plates (Figures b and S11a). They also showed overall fewer surviving colonies for
the triple-target (NS1 + NS3 + NS4) constructs than the double-target
(NS1 + NS4) ones.The induced transformants expressing the [B]
(NS1 + NS4) construct
showed a large variation in editing efficiency (Figure c). For fully segregated colonies, the double-target
editing efficiency ranged from 8 to 100%. Several screened colonies
were edited only in one target or showed incomplete segregation; some
of these latter ones could be pushed toward full segregation by restreaking
on new inducer plates. It is likely that the segregation-resistant
colonies had escaped the action of CRISPR/Cas9 by mutating it, thereby
remaining unedited but still viable. For the [B] + LVA (NS1 + NS4)
construct, restreaking incompletely segregated colonies in a second
round of induction ultimately yielded some double mutants (Figure S11b). However, for the [E*](104) (NS1
+ NS4) construct, while all screened colonies were fully segregated
at the NS4-target (Figure S11b), there
was no trace of editing in the NS1 target and a second round of induction
was not attempted.For the [B] (NS1 + NS3 + NS4) construct,
only after a second round
of induction were a few fully segregated triple mutants identified
(Figure d). Several
more colonies were almost but not yet fully segregated. The poor segregation
of edits was observed mainly at the NS3-target site, which was known
from the single-target data to be less amenable to editing than NS1
or NS4.For the [B] + LVA (NS1 + NS3 + NS4) construct, edits
were generally
rare in any of the targets (Figure S11c); likely this weakest CRISPR/Cas9 construct was too weak to support
this multiediting attempt. For the [E*](104) (NS1 + NS3 + NS4) construct,
the high survival on theophylline (Figure S11a) combined with a few edits (Figure S11c) indicated that these had likely mutated the CRISPR/Cas9. Possibly
the CRISPR/Cas9 activity for these [E*](104) constructs was too strong,
causing cells to die from too rapidly occurring multiple DSBs or having
already “escaped” the CRISPR/Cas9 by selecting against
the effects of a leaky cas9-expression.The
different multiplexing successes for the varyingly strong CRISPR/Cas9
constructs highlight the usefulness in having these options. Overall,
the medium-strength construct [B] performed the best. Taken together,
these results showed that multiplexed CRISPR/Cas9 editing using one
single-target vector is possible in S6803.
Evaluating a Nickel-Inducible Curing System To Clear Mutants
of the CRISPR/Cas9 Vector
A desirable feature of a CRISPR/Cas9
vector is that it should be easily cleared from cells after editing,
leaving the mutant free of antibiotic resistance markers. A common
curing method is to grow edited cells without selecting for the vector,
plate this, and screen colonies for plasmid loss. This method would
likely be inefficient for the CRISPR/Cas9 vectors developed in this
study, as RSF1010-replicon vectors are stably maintained in S6803
for prolonged periods under nonselective conditions.[46] Another option is to add a counter-selection marker to
the vector, such as sacB from Bacillus
subtilis that causes sucrose sensitivity.[47] However, this sacB method is
only functional for the glucose-tolerant subset of wild-type S6803
strains.[48,49] An alternative counter-selection system
developed to work in all wild-type strains of S6803 is based on the
endoribonuclease-encoding mazF from E. coli that causes protein synthesis inhibition
and ultimately cell death.[48] This mazF was here tested for its ability to drive inducible
curing of the pPMQAK1-CRISPR/Cas9 vector. A Ni2+-inducible
promoter was used to drive mazF expression, making
its expression separately controlled from the CRISPR/Cas9 vector.
Two Ni2+-inducible promoters, both native to S6803, were
compared to identify the most suitable. P drives expression of the Ni2+-resistance operon
(nrsBACD) and is controlled by the Ni2+-sensing NrsS and transcriptional regulator NrsR.[50] P drives only nrsD expression and is controlled by the InrS transcriptional regulator.[51] As both promoters are native to S6803, the regulators
are encoded from its own genome. To reduce the risk of premature toxicity
from leaky mazF expression, it was combined with
either of two ssrA protease degradation tags: one
stronger (LVA) and one weaker (AAV).[41] This
gave four different combinations of the mazF-curing
system to test.The four curing system combinations were evaluated
in S6803 by adding them onto the [B]-variant CRISPR/Cas9 base vector
that has lacZ in place of an sgRNA and donor DNA
(Figures a and S3b). When electroporated into S6803, the vectors
with either P-mazF system resulted in few surviving transformants (Figure b), likely due to a lethal
level of leaky mazF expression. The vectors with
the P-mazF variants
yielded colonies in a comparable number to the control vector lacking
any curing system (Figure b). No clear difference could be observed between the vectors
with P-mazF combined
with either the LVA-tag or the AAV-tag. On plates supplemented with
5 μM Ni2+, there were no or few transformants for
either of the P-mazF vectors (Figure b), indicating that induction of the toxic mazF was
successful. Despite P being reported
to be both Ni2+- and Co2+-inducible,[51,52] induction by Co2+ appeared negligible as plating on regular
BG11 (containing 0.17 μM Co2+), Co2+-free
BG11, or plates with 4 μM Co2+ produced similar results
(Figure b).
Figure 6
Evaluating
a Ni2+-inducible curing system for the pPMQAK1-CRISPR/Cas9
vector. (A) Schematic showing the pPMQAK1-CRISPR/Cas9 base vector
supplemented with the best performing curing system: P-mazF-LVA. The other evaluated
curing systems featured either the P- or the P-promoter, and either an
LVA- or an AAV-tag added to mazF. (B) Transformation
results for [B] base vectors supplemented with the indicated curing
system. A control [B] base vector without a curing system was included.
Transformed cells were plated on regular BG11-plates, plates without
any Co2+, or ones with 4 μM Co2+ or 5
μM Ni2+. (C) Ni2+-induction spot assay
results for S6803 containing the [B] base vectors, either supplemented
with P-mazF-LVA or
P-mazF-AAV, or a
control lacking a curing system. 5× dilution series were plated
on nonselective (no kanamycin) or selective plates supplemented with
0, 5, 7, and 10 μM Ni2+. Done for biological triplicates,
representative data are shown. (D) Resulting colonies after Ni2+-induction were screened for curing of the pPMQAK1-CRISPR/Cas9
vector. Screening was done of the kmR-gene found
on the pPMQAK1-backbone. Screening results for the Ni2+-induced [B] (control) or [B] + P-mazF-LVA base vectors are shown. For each induced
biological triplicate, eight colonies were screened. A red line below
a lane signals a fully cured mutant. Colonies that appear cured but
have not been marked as such is due to them having detectable traces
of a pPMQAK1-originating band when gels are more closely inspected.
(E) Triplicate NS1-edited, fully segregated mutants induced on nonselective
BG11-plates with 10 μM Ni2+ were screened for pPMQAK1-vector
curing. For each induced biological triplicate, eight colonies were
screened. A red line below a lane signals a fully cured mutant. Colonies
that appear cured but have not been marked as such are due to them
having detectable traces of a pPMQAK1-originating band when gels are
more closely inspected.
Evaluating
a Ni2+-inducible curing system for the pPMQAK1-CRISPR/Cas9
vector. (A) Schematic showing the pPMQAK1-CRISPR/Cas9 base vector
supplemented with the best performing curing system: P-mazF-LVA. The other evaluated
curing systems featured either the P- or the P-promoter, and either an
LVA- or an AAV-tag added to mazF. (B) Transformation
results for [B] base vectors supplemented with the indicated curing
system. A control [B] base vector without a curing system was included.
Transformed cells were plated on regular BG11-plates, plates without
any Co2+, or ones with 4 μM Co2+ or 5
μM Ni2+. (C) Ni2+-induction spot assay
results for S6803 containing the [B] base vectors, either supplemented
with P-mazF-LVA or
P-mazF-AAV, or a
control lacking a curing system. 5× dilution series were plated
on nonselective (no kanamycin) or selective plates supplemented with
0, 5, 7, and 10 μM Ni2+. Done for biological triplicates,
representative data are shown. (D) Resulting colonies after Ni2+-induction were screened for curing of the pPMQAK1-CRISPR/Cas9
vector. Screening was done of the kmR-gene found
on the pPMQAK1-backbone. Screening results for the Ni2+-induced [B] (control) or [B] + P-mazF-LVA base vectors are shown. For each induced
biological triplicate, eight colonies were screened. A red line below
a lane signals a fully cured mutant. Colonies that appear cured but
have not been marked as such is due to them having detectable traces
of a pPMQAK1-originating band when gels are more closely inspected.
(E) Triplicate NS1-edited, fully segregated mutants induced on nonselective
BG11-plates with 10 μM Ni2+ were screened for pPMQAK1-vector
curing. For each induced biological triplicate, eight colonies were
screened. A red line below a lane signals a fully cured mutant. Colonies
that appear cured but have not been marked as such are due to them
having detectable traces of a pPMQAK1-originating band when gels are
more closely inspected.To determine reliable curing conditions, S6803
transformed with
either of the P-mazF-supplemented [B] base vectors were plated on BG11-plates with 5,
7, or 10 μM Ni2+. Ni2+-induced expression
of the toxic mazF by either of the tested curing
systems caused cell death for a majority of the cells (Figure c). Nonselective plates (no
kanamycin) were used to allow for cured colonies to grow, while selective
plates were included to assess the frequency of colonies that managed
to escape the mazF counter-selection. Cells containing
the vector with P-mazF-LVA showed a distinct difference in the number of background colonies
on selective Ni2+-plates, where the highest 10 μM
Ni2+ gave the lowest level of background (Figure c). Cells containing the vector
with P-mazF-AAV showed
no background already at 5 μM Ni2+, in line with
the AAV-tag being a weaker degradation tag than LVA and supporting
higher mazF levels at lower Ni2+ concentrations.
It was decided that the weaker but titratable LVA system would be
more suitable for use with the CRISPR/Cas9 vectors. Colonies that
grew on Ni2+-supplemented, nonselective plates were screened
by colony-PCR to determine if they had been cured, i.e., if all traces
of the pPMQAK1-vector were gone. The results showed that without Ni2+, the stability of the vector with P-mazF-LVA was comparable to the control vector
lacking a curing system, indicating tight control of the curing system
(Figure d). When exposed
to Ni2+, the stability of the control vector was unaffected
while the cellular amount of the vector with P-mazF-LVA was dramatically reduced (Figure d). The curing was
most efficient at 10 μM Ni2+. Depending on the biological
replicate, 37.5–75% of screened colonies were cured, a significant
improvement over the 0% for the control.To ensure that addition
of P-mazF-LVA to
the [B] CRISPR/Cas9 vector did not have a negative
impact on gene editing, its editing ability was compared to a control
vector lacking a curing system. Several previously tested edit targets
were revisited, and the results showed that the moderate editing efficiency
of yfp (Δ20 bp), the high editing efficiency
of NS1 (Δ30 bp), and multiplexed editing of NS1 + NS4 (Δ30
bp) were all maintained with the new P-mazF-LVA supplemented [B] vector (Figure S12b–d). The number of obtained transformants
was also comparable (Figure S12a). Additionally,
Ni2+-induction of NS1-edited cells resulted in vector curing
in 25–62.5% of screened colonies, showing that the curing system
remains intact following a CRISPR/Cas9 edit step (Figure e). These results are expected
to also apply to the [B] + LVA and [E*](104) vector variants, as the
curing is independent of the CRISPR/Cas9 and induced separately.
Assessing the Final CRISPR/Cas9 System by Targeting the Commonly
Tested nblA Deletion Target
Lastly, we aimed
to compare the inducible, curable CRISPR/Cas9 system described in
this study to a plasmid-delivered Cpf1-based CRISPR system that has
been characterized in S6803 previously.[17,53] A direct comparison
is difficult due to the different PAM requirements and therefore protospacer
selection for these two endonucleases.[9] For an indirect comparison, we targeted the two genes nblA1–2 (nonbleaching protein A) for deletion using a Cas9-compatible spacer
that targeted as close as possible to the previously evaluated Cpf1-compatible
target site (Figure a). Due to the different cleavage mechanisms of Cas9 and Cpf1,[12,54] the designed sgRNA directed the Cas9 to make a blunt DSB in the
same area, as the Cpf1 had previously been directed to make a staggered
cut. Unlike previously tested sgRNAs in this study, this one targeted
the nontemplate strand of the target. The same donor DNA as specified
in the Cpf1-studies, with 1 kb long homology arms,[17,53] was reused here. The editing was attempted with all three P-mazF-LVA-supplemented
CRISPR/Cas9 vectors, i.e., [B], [B] + LVA, and [E*](104). Upon electroporation,
obtained colonies (Figure S13a) were induced
for CRISPR/Cas9 editing on 0.25 mM theophylline. Unexpectedly, most
cells survived this induction (Figure b) and all screened colonies, independent of the CRISPR/Cas9
vector, were found to have the fully segregated nblA1–2 (Δ458 bp) deletion (Figure c). This high editing efficiency was likely due to
leaky CRISPR/Cas9-editing occurring prior to induction. This hypothesis
was confirmed when uninduced colonies from the transformation plates
were screened, the progression of leaky editing was found to correspond
to the potential strength of the CRISPR/Cas9 vector (Figure S13b). It is also possible that the use of a sgRNA
targeting the nontemplate strand, known for resulting in higher on-target
efficiencies,[44] contributed to the observed
leaky editing. Despite this, the fast segregation of this target in
100% of screened colonies stands in contrast to the three induction
rounds required to achieve segregated ΔnblA1–2 with Cpf1.[17,53] Therefore, the described CRISPR/Cas9
system has the potential advantage of reducing the time that is needed
to obtain segregated mutants, despite utilizing a two-step process
where transformation and induced CRISPR/Cas9 editing are done separately.
Figure 7
Evaluating
the deletion (Δ458 bp) of nblA1–2 using
the P-mazF-LVA supplemented
CRISPR/Cas9 vectors. (A) Schematic of the region
between nblA1 and nblA2 in S6803,
showing the relative location of target regions used with Cas9 (this
study) and with Cpf1 (previously published, see main text for references).
Marked in color in the sequence region are the PAMs for either the
Cas9 (blue) or Cpf1 (pink) target regions. The arrowheads indicate
where the Cas9 (blue) or Cpf1 (pink) will introduce DSBs when targeted
to the indicated regions; Cas9 produces blunt DSBs while Cpf1 produces
staggered DSBs. (B) Induction spot assay results for [B], [B] + LVA,
and [E*](104), all supplemented with P-mazF-LVA. 5× dilution series were plated on
regular BG11-plates or ones supplemented with 0.25 mM theophylline
inducer. Done for biological triplicates, representative data is shown.
(C) Editing results of the nblA1–2 deletion
target for [B], [B] + LVA, and [E*](104), all supplemented with P-mazF-LVA. A green line
below a lane signals a fully edited (Δ458 bp) mutant. A control
(“C”) shows how an unedited colony will appear. Fractions
indicated the number of fully edited colonies out of the total number
screened.
Evaluating
the deletion (Δ458 bp) of nblA1–2 using
the P-mazF-LVA supplemented
CRISPR/Cas9 vectors. (A) Schematic of the region
between nblA1 and nblA2 in S6803,
showing the relative location of target regions used with Cas9 (this
study) and with Cpf1 (previously published, see main text for references).
Marked in color in the sequence region are the PAMs for either the
Cas9 (blue) or Cpf1 (pink) target regions. The arrowheads indicate
where the Cas9 (blue) or Cpf1 (pink) will introduce DSBs when targeted
to the indicated regions; Cas9 produces blunt DSBs while Cpf1 produces
staggered DSBs. (B) Induction spot assay results for [B], [B] + LVA,
and [E*](104), all supplemented with P-mazF-LVA. 5× dilution series were plated on
regular BG11-plates or ones supplemented with 0.25 mM theophylline
inducer. Done for biological triplicates, representative data is shown.
(C) Editing results of the nblA1–2 deletion
target for [B], [B] + LVA, and [E*](104), all supplemented with P-mazF-LVA. A green line
below a lane signals a fully edited (Δ458 bp) mutant. A control
(“C”) shows how an unedited colony will appear. Fractions
indicated the number of fully edited colonies out of the total number
screened.
Conclusions
In this study, we designed a riboswitch-based,
theophylline-inducible
CRISPR/Cas9-system for easy use in S6803. This system forgoes the
common issue of Cas9-toxicity, enabling one to attain high transformation
efficiencies for the pPMQAK1-CRISPR/Cas9 target vector. Inducing CRISPR/Cas9
in obtained transformants allowed edited colonies to be isolated.
Single edits were fully segregated after just one passage on the inducer,
reducing the editing time. The system was also shown to support multiplexed
editing in S6803, enabling simultaneous editing of up to three targets
using one single CRISPR/Cas9 vector. The [B] construct was most successful
overall, supporting all attempted single and multiplexed edits. Although,
the stronger [E*](104) and weaker [B] + LVA constructs could be useful
in the case of weak or strong sgRNAs, respectively, that cannot be
redesigned due to, e.g., specific target site requirements. The two-step
workflow, where transformation and CRISPR/Cas9 genome editing are
done separately, was most reliable throughout this study. However,
in some cases (e.g., adding the FLAG-tag to rbcL),
edited colonies could be found among transformants that survived induction
directly after transformation. Finally, the developed CRISPR/Cas9
vectors were equipped with a curing system based on the nickel-inducible
expression of the toxic mazF. The combination of
P and an LVA-tag on the mazF allowed for a tightly controlled curing system that did not interfere
with CRISPR/Cas9 editing and that supported curing in 25–75%
of screened cells.
Methods
Strains and General Growth Conditions
See Table S1 for strains used in this study. The
wild-type S6803 (a gift from Martin Fulda, University of Goettingen)
is a nonmotile GT-S derivative. A Δslr1181::P-Yfp-B0015-Spr strain was
used for yfp genome editing. All cultivations were
done at 30 °C, 1% (v/v) CO2, and 30 (plates) or 50
(liquid) μE s–1 m2, using a Percival
Climatics SE-1100 climate chamber. The BG11 media was buffered to
pH 7.9 with 25 mM HEPES. For growth on solid media, 1.5% (w/v) agar
and 0.3% (w/v) sodium thiosulfate were added to the BG11. When needed,
antibiotics were supplemented (40 μg/mL kanamycin, 40 μg/mL
spectinomycin). Growth in liquid media was monitored by OD730. Special conditions for, e.g., CRISPR/Cas9-induction or plasmid
curing are explained in the following sections.
Vector Construction
For vectors used and constructed
in this study, see Table S1. All the primers
are listed in Table S2. All subcloning
was done in Escherichia coli XL1-Blue.The pPMQAK1-T vector[40] has BpiI sites
ready for Golden Gate cloning.[55] The Gfp
reporter, and CRISPR/Cas9 base vectors were built by amplifying the
required inserts, which added overhangs with compatible BpiI sites,
and performing multipiece assembly into pPMQAK1-T (see more details
as follows). All Golden Gate cloning was done using Thermo Fisher
Scientific T4 DNA ligase and FastDigest BpiI or BsaI (as specified).
All Golden Gate cloning primers were designed using Benchling.[56]The sequences of the evaluated promoters,
P and P, and riboswitches (B,
C, E*) can be seen in the Supporting Information. The combinations
were ordered as “Ultramer”-oligos from IDT.To
build the Gfp reporter plasmids, the gfp and
terminator (BBa_B0015) was amplified as a single piece from a plasmid
available in lab. The promoter-riboswitch pieces were amplified from
the “Ultramer” templates.Before constructing
the CRISPR/Cas9 base vectors, the pPMQAK1-T
vector and cas9 gene were domesticated for use with
BsaI and BpiI, respectively. This was done either by PCR-based site-directed
mutagenesis[57] or subcloning using Golden
Gate assembly. To build the CRISPR/Cas9 base vectors, the following
pieces were amplified and inserted into pPMQAK1-T: the P riboswitch pieces using the “Ultramer”
templates, the BpiI-free cas9 gene, a BBa_B0015 terminator,
and the lacZ gene as found in the pPMQAK1-T with
extra added BsaI sites on either side for future cloning use. For
the promoterless-cas9 control vector, the P riboswitch piece was left out. The constructed
pPMQAK1-CRISPR/Cas9 base vectors, with P riboswitch (B, C, or E*), were used in site-directed mutagenesis[57] to make variants with an LVA-tag on Cas9, and
variants with a weaker −10-box in P.For the P-mazF-LVA/AAV or P-mazF-LVA/AAV supplemented CRISPR/Cas9 base vectors, the promoters (see
the Supporting Information for sequences) and mazF (with added LVA- or AAV-tag) were added as extra pieces in the base
vector assembly described above. P and P were amplified from the S6803
genome, while mazF was amplified from E. coli cells.The pPMQAK1-CRISPR/Cas9 target
vectors were built by Golden Gate
cloning; the sgRNA and donor DNA were simultaneously inserted using
the BsaI sites in the selected CRISPR/Cas9 base vector. The BsaI-containing
overhangs added to the 5′- and 3′-ends of the amplified
sgRNA and donor DNA were kept constant, see Supporting Information
for details.The single-target sgRNAs were constructed by overlap-PCR,
using
the compatible spacer sequences added as overhangs to the BBa_J23117
promoter piece and the Cas9-handle-S. pyogenes-terminator piece. An example sgRNA sequence can be seen in the Supporting
Information. For the multiplex target vectors, the sgRNAs were first
combined into an array by Golden Gate subcloning in a pMD19-backbone.
This sgRNA array construction was done as described by Li et al.[45] The final pMD19-sgRNA array plasmid contained
the necessary BsaI sites flanking the array, so it was directly added
to the target vector Golden Gate assembly. The sgRNA spacers in this
study (Table S3) were designed using Benchling.[56] Off-target binding analysis (Table S4) was done using Benchling[56] and the CasOT software.[58]The donor
DNAs were prepared by overlap-PCR of the amplified homology
arms. An exception was when inserting the P-Yfp-B0015 cassette into slr0168; here, the
two homology arms and cassette were supplied as three separate pieces.
For the multiplex target vectors, the donor DNA for each site was
prepared separately, with overhangs as shown in Figure a.
Strain Construction
All constructed pPMQAK1 vectors
were transformed into S6803 by electroporation, see Supporting Information
for details. Each transformation used 5–10 mL exponentially
growing S6803 (OD730 0.6–1), and 100–350
ng of vector DNA. Cells were recovered for 16–24 h, before
plating on selective media. For CRISPR/Cas9 vectors the recovered
cells were pelleted, resuspended in 460 μL BG11, whereby 200
μL each was plated on selective BG11-plates without or with
0.25 mM theophylline. For preparation and use of the 200 mM theophylline
stock, see the Supporting Information. In some cases (e.g., the yfp edit, and testing the mazF-supplemented
vectors), the remaining cell suspensions were used to make spot assays
(10 μL spots).
Inducing CRISPR/Cas9 Genome Editing
Induction was done
on solid media. BG11-plates were supplemented with 0.25 mM (or as
indicated) theophylline. Induction was done for biological triplicates
(i.e., separate colonies from one transformation) in all cases except
for the biological duplicates used for the single-target editing of
NS1, 2, 3, or 4. For the yfp (Δ20 bp) edit,
induction of the biological triplicates was also prepared in technical
duplicates. Due to the similar results between these technical duplicates
(Figure e), such technical
replicates were not included for any of the following inductions.
Transformants used for inductions always came from freshly prepared
transformations (no older than 4 weeks); all strains compared in one
induction experiment were always transformed on the same day. Induction
was done in one of two ways; transformants were picked into precultures
(∼2–3 mL, done in 24-deep well plates) and cultivated
for 3–4 days before plated on inducer plates, or transformant
colonies were suspended in a small volume (∼50–80 μL)
of BG11 and directly plated on inducer plates. The latter method is
recommended. The described precultures or colony suspensions were
diluted before plating on inducer plates. The prepared “base”-dilution
was OD730 0.2, from which a 5× dilution series was
prepared. The dilution series were used to make spot assays (4 μL
spots) on indicated plate types, and the remaining volume (40–60
μL) of selected dilutions (commonly 5×, 25×, 125×)
was then plated on full-size inducer plates, see Supporting Information
for details. After 10–14 days, healthy-looking colonies were
screened. If needed, colonies with unsegregated edits were restreaked
on new inducer plates.
Evaluating Genome Editing and Screening Mutants
After
CRISPR/Cas9-induction, surviving healthy-looking colonies were screened
by colony-PCR. The editing efficiency was the percentage of edited
colonies found among the ones screened. The second quantification
used, the percentage of induced CFUs that survived and also became
edited, was calculated by relating the found editing efficiency to
the percentage of induced CFUs that retained a healthy phenotype (i.e.,
“survived”). This latter percentage was estimated from
the spot assays prepared for every editing experiment; the total plated
CFUs and surviving, healthy-looking CFUs were estimated from the plates
without or with theophylline, respectively. Healthy-looking meant
colonies that were not bleached, but instead green and had managed
to grow well on the inducer plates. Raw data for these CFU calculations
can be seen in Table S5.For the
RbcL-FLAG immunoblot, 15 μg protein (soluble fraction) was separated
by SDS-PAGE, transferred onto a 0.45 μm PVDF membrane, and analyzed
using the WesternBreeze Chromogenic anti-mouse kit with a primary
anti-FLAG (F4042, Sigma-Aldrich) antibody at a 4000× dilution.
Cells were lysed by bead beating (200 μL beads, 10 min total,
1 min on/off, 4 °C) in lysis buffer (50 Tris–HCl, 150
mM NaCl, Roche complete EDTA-free protease inhibitor); centrifugation
for 30 min at 4 °C and 21,000 × g allowed
isolation of the soluble fraction supernatant.
Curing of pPMQAK1-CRISPR/Cas9 Vectors
For evaluation
of the optimal curing conditions, triplicate colonies were suspended
separately in a small volume of BG11 and then plated on selective
and nonselective (without kanamycin) BG11-plates supplemented with
0, 5, 7, or 10 μM Ni2+ (added using a 50 mM NiSO4 stock). Both spot plates (4 μL spots of a 5× dilution
series) and spreading on full-sized plates was done. The resulting
colonies were screened for pPMQAK1-loss (i.e., curing) by screening
for the plasmid-encoded kanamycin-resistance cassette by colony-PCR.Curing of edited, fully segregated colonies was performed by suspending
them in a small volume of BG11 (∼80 μL) and spreading
this on nonselective (without kanamycin) BG11-plate supplemented 10
μM Ni2+. Screening resulting colonies for pPMQAK1
loss was done as described above.
Authors: Yi Xiao; Shaojie Wang; Sarah Rommelfanger; Andrea Balassy; Carlos Barba-Ostria; Pengfei Gu; Jonathan M Galazka; Fuzhong Zhang Journal: Biotechnol Bioeng Date: 2018-06-29 Impact factor: 4.530
Authors: Ryan Clarke; Robert Heler; Matthew S MacDougall; Nan Cher Yeo; Alejandro Chavez; Maureen Regan; Leslyn Hanakahi; George M Church; Luciano A Marraffini; Bradley J Merrill Journal: Mol Cell Date: 2018-07-05 Impact factor: 17.970